Abstract:Background: The differentiation of pericytes into myofibroblasts causes microvascular degeneration, ECM (extracellular matrix) accumulation, and tissue stiffening, characteristics of fibrotic diseases. It is unclear how pericyte-myofibroblast differentiation is regulated in the microvascular environment. Our previous study established a novel 2-dimensional platform for coculturing microvascular endothelial cells (ECs) and pericytes derived from the same tissue. This study investigated how ECM stiffness regulated microvascular ECs, pericytes, and their interactions. Methods: Primary microvessels were cultured in the TGM2D medium (tubular microvascular growth medium on 2-dimensional substrates). Stiff ECM was prepared by incubating ECM solution in regular culture dishes for 1 hour followed by PBS wash. Soft ECM with Young modulus of ≈6 kPa was used unless otherwise noted. Bone grafts were prepared from the rat skull. Immunostaining, RNA sequencing, RT-qPCR (real-time quantitative polymerase chain reaction), Western blotting, and knockdown experiments were performed on the cells. Results: Primary microvascular pericytes differentiated into myofibroblasts (NG2+αSMA+) on stiff ECM, even with the TGFβ (transforming growth factor beta) signaling inhibitor A83-01. Soft ECM and A83-01 cooperatively maintained microvascular stability while inhibiting pericyte-myofibroblast differentiation (NG2+αSMA-/low). We thus defined 2 pericyte subpopulations: primary (NG2+αSMA-/low) and activated (NG2+αSMA+) pericytes. Soft ECM promoted microvascular regeneration and inhibited fibrosis in bone graft transplantation in vivo. As integrins are the major mechanosensor, we performed RT-qPCR screening of integrin family members and found Itgb1 (integrin β1) was the major subunit downregulated by soft ECM and A83-01 treatment. Knocking down Itgb1 suppressed myofibroblast differentiation on stiff ECM. Interestingly, ITGB1 phosphorylation (Y783) was mainly located on microvascular ECs on stiff ECM, which promoted EC secretion of paracrine factors, including CTGF (connective tissue growth factor), to induce pericyte-myofibroblast differentiation. CTGF knockdown or monoclonal antibody treatment partially reduced myofibroblast differentiation, implying the participation of multiple pathways in fibrosis formation. Conclusions: ECM stiffness and TGFβ signaling cooperatively regulate microvascular stability and pericyte-myofibroblast differentiation. Stiff ECM promotes EC ITGB1 phosphorylation (Y783) and CTGF secretion, which induces pericyte-myofibroblast differentiation.

Matrix Stiffness Induces Pericyte-Fibroblast Transition Through YAP Activation

Stiffer Matrix Accelerates Migration of Hepatocellular Carcinoma Cells Through Enhanced Aerobic Glycolysis Via the MAPK-YAP Signaling

Matrix Stiffness Controls Cardiac Fibroblast Activation Through Regulating YAP Via AT1 R.

Matrix Stiffening Facilitates the Collective Invasion of Breast Cancer through the Periostin-Integrin Mechanotransduction Pathway

Pin1/YAP pathway mediates matrix stiffness‐induced epithelial–mesenchymal transition driving cervical cancer metastasis via a non‐Hippo mechanism

The Matrix Stiffness Coordinates the Cell Proliferation and PD-L1 Expression via YAP in Lung Adenocarcinoma

Matrix stiffness modulates tip cell formation through the p-PXN-Rac1-YAP signaling axis

Aligned fibrous scaffolds promote directional migration of breast cancer cells via caveolin-1/YAP-mediated mechanosensing

The Role of Matrix Stiffness in Cancer Stromal Cell Fate and Targeting Therapeutic Strategies

Matrix Stiffness Contributes to Cancer Progression by Regulating Transcription Factors

PIEZO1 mediates matrix stiffness-induced tumor progression in kidney renal clear cell carcinoma by activating the Ca2+/Calpain/YAP pathway

Focal Adhesion Assembly in Myofibroblasts Fosters a Microenvironment That Promotes Tumor Growth

Matrix Stiffening Facilitates Stemness of Liver Cancer Stem Cells by YAP Activation and BMF Inhibition

Matrix Stiffness Promotes Hepatoma Cell Glycolysis and Migration Through YAP-Mediated Mechanotransduction

Matrix Stiffness-Driven Cancer Progression and the Targeted Therapeutic Strategy

Stromal softness confines pancreatic cancer growth through lysosomal-cathepsin mediated YAP1 degradation

YAP Inactivation by Soft Mechanotransduction Relieves MAFG for Tumor Cell Dedifferentiation

3D matrix stiffness modulation unveils cardiac fibroblast phenotypic switching

Matrix stiffening from collagen fibril density and alignment modulates YAP-mediated T-cell immune suppression

Stiff substrates increase YAP-signaling-mediated matrix metalloproteinase-7 expression

Extracellular Matrix Stiffness Regulates Microvascular Stability by Controlling Endothelial Paracrine Signaling to Determine Pericyte Fate